Tests ivabradine against placebo in cardiogenic shock after heart attack
Tests ivabradine tablets against placebo in adults with cardiogenic shock after heart attack.
Plain-language title generated from the registry record
Registry title: Ivabradine in the Acute Management of Cardiogenic Shock
Key facts
- Where
- Karachi, PakistanSee the site
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07714746, who can take part
Where in Pakistan
- National Institute of Cardiovascular DiseasesKarachi, PakistanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National Institute of Cardiovascular Diseases, Pakistan
- Trial code
- NCT07714746
- Record updated
- 20 July 2026
- Original description
Brief Summary:Read full original descriptionShow less
Ivabradine in the Acute Management of Cardiogenic Shock - IVASHOCK-a Double-blind Randomized Controlled Trial
Brief Summary:
The IVASHOCK trial investigates whether ivabradine can achieve at least one-class improvement in SCAI cardiogenic shock classification compared to placebo, and evaluates its safety profile in patients with cardiogenic shock (CS).
Primary Objectives:
1. To determine whether ivabradine improves SCAI shock classification by at least one class from baseline within 72 hours compared to placebo 2. To assess whether ivabradine facilitates earlier weaning from vasoactive and inotropic support compared to placebo
Safety Endpoints:
Adverse events monitored include: sinus node dysfunction, new-onset atrial fibrillation or atrial flutter, atrioventricular block, drug-related hypotension, and ventricular arrhythmia.
Participant Schedule:
Participants will receive ivabradine or placebo orally every 12 hours for 3 days.
Hemodynamic and metabolic assessments will include:
Arterial pH, central venous oxygen saturation (ScvO2), and serum lactate - every 6 hours on Day 1, then every 8 hours on Days 2 and 3 Heart rate, mean arterial pressure (MAP), vasoactive/inotropic support dose, and urine output - measured on the same timeline
Inclusion: Patients aged 18-75 years diagnosed with STEMI complicated by cardiogenic shock (CS) as defined by SCAI shock classification > C:; Signs of Hypoperfusion including:; SBP <90 OR MAP <60 OR >30 mmHg drop from baseline AND drugs/device used to maintain BP above these targets; Cold, clammy extremities; Urine output <30 mL/h; pulmonary congestion (either crackles, congestion in chest X-ray or B-lines in lung US); Mixed venous oxygen saturation ≤ 65%; Severe Left ventricular (LV) dysfunction or right ventricular (RV) infarction; Heart rate (HR) ≥ 100 bpm (Sinus Rhythm) in whom beta-blocker therapy cannot be initiated, including: On inotropic or vasopressor support, Requiring an intra-aortic balloon pump (IABP), With Killip class III or IV, Requiring BiPAP or mechanical ventilation.
Exclusion: Extensive comorbidities; Prior CVA, Malignancy, Pregnancy or Ongoing Participation in Other Trials; Complete Heart Block; Heart rate of < 100 bpm; End stage Renal Disease; Age > 75 years; CPR > 12 mints; Atrial fibrillation.